Patents Assigned to INSERM (Institut National de la Santé et de la Recherche Médicale)
-
Publication number: 20220273582Abstract: A continuous process for nano-emulsification that is performed by concentration phase inversion in a microfluidic reactor, including the following steps: (a) injection of an aqueous phase into a first microchannel, the first microchannel opening onto a formulation chamber, (b) injection, into a second microchannel, of a fatty phase including one or more fatty substances immiscible in the aqueous phase, and one or more surfactants, the second microchannel opening into the formulation chamber, then (c) mixing of the aqueous phase and the fatty phase in the formulation chamber, then (d) recovering, at the output of the formulation chamber, a suspension including lipid nanocapsules. Also, the lipid nanocapsules obtainable by the process, and the use of the lipid nanocapsules as nanovectors for pharmacologically active ingredients.Type: ApplicationFiled: July 24, 2020Publication date: September 1, 2022Applicants: UNIVERSITÉ D'ANGERS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Brice CALVIGNAC, Jean-Christophe GIMEL, Emilie ROGER, Nicolas ROLLEY, Guillaume LEFEBVRE, Guillaume BASTIAT, Florian FOUCHET, Kévin MATHA
-
Publication number: 20220275105Abstract: A method for providing cardioprotection in a subject who experienced a myocardial infarction, including administering a therapeutically effective amount of a Granzyme B inhibitor. Following acute MI in mice, CD8+ T lymphocytes are quickly recruited and activated in ischemic heart tissue, and release Granzyme B, leading to cardiomyocyte apoptosis and deterioration of myocardial function. Antibody-mediated depletion of CD8+ T lymphocytes decreases Granzyme B content and apoptotic within the myocardium and inflammatory response. mAb mediated-CD8 depletion limits myocardial injury and improves heart function. These effects are recapitulated in mice with CD8+ T cell selective Granzyme B deficiency in mice. Granzyme B is produced by other cell types (e.g., NK cells). Global Granzyme B deletion (GzmB-/- mice) decreases apoptotic within the myocardium, reduces local pro-inflammatory signature and ultimately limits infarct size after MI.Type: ApplicationFiled: July 31, 2020Publication date: September 1, 2022Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), SORBONNE UNIVERSITÉ, UNIVERSITÉ DE PARISInventors: Hafid AIT-OUFELLA, Nicolas DANCHIN, Icia SANTOS ZAS, Tabassome SIMON
-
Patent number: 11427824Abstract: The present invention relates to compositions and methods for the treatment of myotonic dystrophy.Type: GrantFiled: October 27, 2017Date of Patent: August 30, 2022Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Ana Maria Buj Bello, Mirella Lo Scrudato
-
Patent number: 11427836Abstract: An RNA interference (RNAi) strategy is provided based on use of artificial microRNA (amiR) to reduce NKCC1 expression. In particular, a method is provided that achieves neuron-specific expression of specific amiR against NKCC1 by using a human Synapsin promoter to drive transgene expression.Type: GrantFiled: April 11, 2018Date of Patent: August 30, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITE D'EVRY-VAL-D'ESSONNE, GENETHON, FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, FONDAZIONE TELETHONInventors: Federico Mingozzi, Giuseppe Ronzitti, Andrea Contestabile, Laura Cancedda
-
Patent number: 11427648Abstract: The present invention relates to the field of diagnostic and treatment of cancer, particularly melanoma, pancreatic cancer, kidney cancer and colon cancer. In particular, the invention relates to an antibody directed specifically to CD146-positive tumors and its applications, particularly for use as a medicament for the prevention and/or treatment of cancer, for use in a method of diagnostic or prognostic of a cancer, or for use as a radiotracer when labelled with a radioactive element.Type: GrantFiled: October 5, 2018Date of Patent: August 30, 2022Assignees: UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Marcel Blot-Chabaud, Benjamin Guillet, Marie Nollet, Jimmy Stalin, Nathalie Bardin, Françoise Dignat-George
-
Publication number: 20220251232Abstract: Novel anti-CD25 antibodies and antigen-bind fragments thereof that do not inhibit the binding of interleukin-2 (IL-2) to CD25, and the use thereof for treating cancer or an infectious disease. Also, fusion proteins including the antibodies and antigen-bind fragments, nucleic acids encoding the antibodies and antigen-bind fragments, and an expression vectors including the nucleic acids. Further, pharmaceutical compositions including the fusion proteins or the antibodies and antigen-bind fragments.Type: ApplicationFiled: May 20, 2020Publication date: August 11, 2022Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE PARIS, ALDERAAN BIOTECHNOLOGY, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Arnaud FOUSSAT
-
Patent number: 11406686Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of tissue lesions. The inventors showed that CCR2 is expressed on FMCs, especially on a subpopulation of progenitor cells, that they call “fetal myeloid progenitor cells” (FMPCs), and mediates the recruitment of these cells to maternal wound tissue. Moreover, the inventors reported that recruited FMCs/FMPCs improve maternal skin wound healing by organizing blood vessel endothelium and secreting pro-angiogenesis peptides, particularly chemokine CXCL1, to enhance angiogenesis in wound. In particular, the present invention relates to CCR2 agonists for use in the treatment of tissue lesions in a subject in need thereof.Type: GrantFiled: May 2, 2017Date of Patent: August 9, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Sorbonne Université, Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (APHP)Inventors: Selim Aractingi, Mathieu Catela, Dany Nassar, Zhe Wang
-
Publication number: 20220233673Abstract: A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.Type: ApplicationFiled: June 4, 2020Publication date: July 28, 2022Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), COMMISSARIAT Á L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Anne BILLET, Frédéric SCHMIDT, Ludger JOHANNES, Denis SERVENT, Gilles MOURIER, Éric TARTOUR, Michael KAY, James M. FULCHER
-
Publication number: 20220233250Abstract: Systems, instruments, and methods are provided verifying the surgery is being performed in accordance with a surgical plan, wherein a surgical tool having a sensor outputs a data signal that enables the trajectory of the surgical tool to be displayed as an overlay on an image of an anatomical portion of a patient and a visual or audible signal that confirms the surgical tool is penetrating the anatomical portion in accordance with the surgical plan and/or that issues an alert indicating that the surgical tool is not being inserted into the anatomical portion according to the surgical plan.Type: ApplicationFiled: April 13, 2022Publication date: July 28, 2022Applicants: SpineGuard, INSERM (Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique - CNRSInventors: Stephane BETTE, Maurice BOURLION, Thibault CHANDANSON
-
Patent number: 11389489Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.Type: GrantFiled: June 8, 2020Date of Patent: July 19, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, UNIVERSITE DE ROUEN, TARGEDYSInventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Naouel Tennoune, Romain Legrand
-
Patent number: 11390866Abstract: The present invention relates to a nucleic acid sequence derived from the regulatory region of the human gamma-synuclein gene and having a promoter activity in retinal ganglion cells. The present invention also relates to expression cassettes or vectors comprising said promoter operably linked to a nucleic acid sequence encoding a polypeptide of interest as well as viral particles or host cells comprising said expression cassette or vector. The present invention also relates to the use of said expression cassettes, vectors, viral particles or cells in the treatment of ocular disease, in particular ocular disease associated with retinal ganglion cell or photoreceptor cell degeneration.Type: GrantFiled: December 5, 2016Date of Patent: July 19, 2022Assignees: SORBONNE UNIVERSITÉ, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Deniz Dalkara, Serge Picaud, Melissa Desrosiers, Jose-Alain Sahel, Jens Duebel, Alexis Bemelmans, Botond Roska
-
Patent number: 11382894Abstract: The inventors demonstrate that the phosphatase and hydrolase domains of soluble epoxide hydrolase (sEH) regulate the cardiovascular calcification process and revealed that inhibition of the phosphatase domain of sEH could represent a new pharmacological target in the prevention of cardiovascular calcification. The present invention thus relates to a therapeutically effective amount of an inhibitor of phosphatase activity of soluble epoxide hydrolase for use in a method of treating cardiovascular calcification in a subject in need thereof.Type: GrantFiled: March 29, 2018Date of Patent: July 12, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE ROUEN NORMANDIE, UNIVERSITE DE PICARDIE JULES VERNE, CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, CENTRE HOSPITALIER UNIVERSITAIRE D'AMIENSInventors: Jeremy Bellien, Isabelle Six, Romuald Mentaverri, Said Kamel
-
Patent number: 11384351Abstract: The present invention relates to the field of nucleic acid purification. In particular, it relates to methods and tools for purifying nucleic acids in a sample; which are compatible with high-throughput sequencing and diagnosis. The inventors have shown that nucleic acid binding proteins recruited to polymerized tubulin (i.e. microtubules) could, subsequently, be isolated from cell lysates. Surprisingly, it has now been found that the amount of recovered nucleic acid found in these microtubule pellets increases dramatically in the presence of nucleic acid-trapping proteins comprising a nucleic acid-binding moiety and a polymerized tubulin-binding moiety, by comparison to proteins devoid of the nucleic acid-binding moiety; and that the recovery of the purified nucleic acids was itself particularly efficient. This purification method is particularly amenable to high-throughput sequencing and/or in the context of a diagnosis method for identifying or comparing the amount of nucleic acids in a set of samples.Type: GrantFiled: July 27, 2018Date of Patent: July 12, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY—VAL D'ESSONEInventors: David Pastre, Bénédicte Desforges, Alexandre Maucuer
-
Patent number: 11383004Abstract: The present invention relates to methods for adhering tissue surfaces and materials and biomedical uses thereof. In particular the present invention relates to a method for adhering a first tissue surface to a second tissue surface in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on at least one of the tissue surfaces, and approximating the surfaces for a time sufficient for allowing the surfaces to adhere to each other. The present invention also relates to a method for adhering a material to a biological tissue in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on the surface of the material and/or the biological tissue and approximating the material and the biological tissue for a time sufficient for allowing the material and the biological tissue to adhere to each other.Type: GrantFiled: April 1, 2019Date of Patent: July 12, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS CITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS XIII PARIS-NORD, ÉCOLE SUPÉRIEUR DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE PARIS, SORBONNE UNIVERSITEInventors: Ludwik Leibler, Anne Meddahi-Pellé, Didier Letourneur, Alba Marcellan-Parisot
-
Patent number: 11383053Abstract: The invention relates to a device for olfactory stimulation of a patient with a plurality of scents, said device comprising: —a source (2) of a carrier gas (G); —a plurality of scent odorization circuits, each odorization circuit (4) comprising: —a container (18) containing an odorous volatile substance (V), —a container inlet line (26), provided with a container inlet valve (28), connecting an inlet (30) of said container with said source of carrier gas, and —a container outlet line (36), provided with a container outlet valve (38), connecting an outlet (40) of said container with an exit line (12); —a control unit (8), configured to control said container inlet valve and container outlet valve according to a medical protocol.Type: GrantFiled: February 2, 2017Date of Patent: July 12, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE JEAN MONNET SAINT ETIENNEInventors: Marc Thevenet, Patricia Viret
-
Patent number: 11376321Abstract: The present invention relates to a method for removing undesired anti-AAV antibodies from a blood-derived composition.Type: GrantFiled: March 1, 2018Date of Patent: July 5, 2022Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITÉ, ASSOCIATION INSTITUT DE MYOLOGIEInventors: Bérangére Bertin, Carole Masurier, Otto-Wilhelm Merten, Federico Mingozzi
-
Patent number: 11371061Abstract: The present invention relates to peptides and compositions for use in improving transduction efficiency of viruses into target cells.Type: GrantFiled: November 30, 2016Date of Patent: June 28, 2022Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY VAL D'ESSONNEInventors: Saliha Majdoul, David Fenard
-
Patent number: 11365251Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).Type: GrantFiled: October 27, 2020Date of Patent: June 21, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar
-
Patent number: 11365257Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.Type: GrantFiled: October 20, 2017Date of Patent: June 21, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, OSE IMMUNOTHERAPEUTICSInventors: Elise Chiffoleau, Géraldine Teppaz, Nicolas Poirier, Bernard Vanhove, Vanessa Gauttier
-
Patent number: 11365392Abstract: The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4+ Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCR??+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCR??+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.Type: GrantFiled: August 4, 2017Date of Patent: June 21, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), MEDECINE ET INNOVATION, UNIVERSITÉ PARIS DIDEROT—PARIS 7, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Daniel Zagury, Helene Le Buanec, Sophie Duchez, Valerie Schiavon, Armand Bensussan